Drug General Information (ID: DDICRV8ZUH)
Drug Name			Tositumomab		Drug Info		Filgrastim		Drug Info
Drug Type		Monoclonal antibody				Protein/peptide
Therapeutic Class		Antineoplastics				Colony Stimulating Factors

Mechanism of Tositumomab-Filgrastim Interaction (Severity Level: Moderate)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Tositumomab				Filgrastim
Mechanism		Reduce therapeutic efficacy of hematopoietic growth factors				Hematopoietic growth factors
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Tositumomab when combined with Filgrastim

Recommended Action
Management		Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.

References
1	Product Information. Granix (tbo-filgrastim). Teva Pharmaceuticals USA, North Wales, PA.
2	Product Information. Leukine (sargramostim). Immunex Corporation, Seattle, WA.
3	Product Information. Stemgen (ancestim) Amgen, Thousand Oaks, CA.